NASDAQ:NBY - NovaBay Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.25 -0.01 (-0.79 %)
(As of 12/16/2018 09:39 AM ET)
Previous Close$1.25
Today's Range$1.20 - $1.26
52-Week Range$0.97 - $4.20
Volume6,782 shs
Average Volume13,346 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Receive NBY News and Ratings via Email

Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:NBY
Previous Symbol
CUSIPN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares17,090,000
Market Cap$0.00
OptionableNot Optionable

NovaBay Pharmaceuticals (NASDAQ:NBY) Frequently Asked Questions

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the NASDAQ under the ticker symbol "NBY."

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NASDAQ:NBY) released its quarterly earnings data on Wednesday, November, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.02. The firm had revenue of $3.14 million for the quarter, compared to the consensus estimate of $4.09 million. View NovaBay Pharmaceuticals' Earnings History.

When is NovaBay Pharmaceuticals' next earnings date?

NovaBay Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 19th 2019. View Earnings Estimates for NovaBay Pharmaceuticals.

What is the consensus analysts' recommendation for NovaBay Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NovaBay Pharmaceuticals.

Has NovaBay Pharmaceuticals been receiving favorable news coverage?

News headlines about NBY stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. NovaBay Pharmaceuticals earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark M. Sieczkarek, Chairman, CEO & Pres (Age 63)
  • Mr. Justin M. Hall, Sr. VP & Gen. Counsel (Age 40)
  • Mr. John J. McGovern, CFO, Treasurer & Principal Accounting Officer
  • Dr. David W. Stroman Ph.D., Sr. VP of Ophthalmic Product Devel. and Chair of Ophthalmology Advisory Board (Age 73)
  • Mr. Lewis J. Stuart BA, MBA, Chief Commercial Officer (Age 59)

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $1.25.

What is NovaBay Pharmaceuticals' official website?

The official website for NovaBay Pharmaceuticals is http://www.novabaypharma.com.


MarketBeat Community Rating for NovaBay Pharmaceuticals (NASDAQ NBY)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe NBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Featured Article: Debt-To-Equity Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel